Clinical Trials
74
Active:53
Completed:1
Trial Phases
3 Phases
Phase 1:58
Phase 2:10
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (71 trials with phase data)• Click on a phase to view related trials
Phase 1
58 (81.7%)Phase 2
10 (14.1%)phase_1_2
2 (2.8%)Not Applicable
1 (1.4%)No trials found
News
Amivantamab Shows Promise in Colorectal Cancer as Phase 3 Trials Launch Following Encouraging Phase 1b/2 Results
The phase 1b/2 OrigAMI-1 trial demonstrated that amivantamab monotherapy achieved a 22% objective response rate and 3.7-month median progression-free survival in advanced colorectal cancer patients.